Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roivant Cuts Multiple R&D Programs As It Takes On Pfizer’s TYK2/JAK1 Inhibitor

Sickle Cell, Dermatology And Cancer Drugs Among Discontinued Assets

Executive Summary

Roivant and Pfizer launched Priovant to develop the oral drug brepocitinib for dermatomyositis, lupus and other autoimmune diseases, but Roivant also cut programs to extend its cash runway.

You may also be interested in...



Deal Watch: Iktos Doubles Its 2022 Alliance Tally In Agreements With Galapagos, Zealand

French AI-driven drug design firm will employ multiple technology platforms in latest tie-ups. Apellis looks to augment Empaveli-led portfolio in C3 complement R&D alliance with Affilogic.

Bristol Confident To Move Deucravacitinib Into Phase III Lupus Trial

A Phase II study testing the TYK2 inhibitor in systemic lupus erythematosus met the primary endpoint. CMO Samit Hirawat talked to Scrip about the data and future development.

Dermavant Prepares For First Launch, Looking To Build A Blockbuster Psoriasis Brand

The Roivant-owned company's Vtama topical cream was approved by the US FDA with a broad label permitting use for mild, moderate or severe psoriasis.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146630

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel